These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 36753564

  • 1. Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models.
    Parker S, McDowall C, Sanchez-Perez L, Osorio C, Duncker PC, Briley A, Swartz AM, Herndon JE, Yu YA, McLendon RE, Tedder TF, Desjardins A, Ashley DM, Gunn MD, Enterline DS, Knorr DA, Pastan IH, Nair SK, Bigner DD, Chandramohan V.
    Sci Transl Med; 2023 Feb 08; 15(682):eabn5649. PubMed ID: 36753564
    [Abstract] [Full Text] [Related]

  • 2. Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.
    Chandramohan V, Bao X, Yu X, Parker S, McDowall C, Yu YR, Healy P, Desjardins A, Gunn MD, Gromeier M, Nair SK, Pastan IH, Bigner DD.
    J Immunother Cancer; 2019 May 29; 7(1):142. PubMed ID: 31142380
    [Abstract] [Full Text] [Related]

  • 3. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.
    Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, Bigner DD.
    Clin Cancer Res; 2013 Sep 01; 19(17):4717-27. PubMed ID: 23857604
    [Abstract] [Full Text] [Related]

  • 4. Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial.
    Chandramohan V, Pegram CN, Piao H, Szafranski SE, Kuan CT, Pastan IH, Bigner DD.
    Appl Microbiol Biotechnol; 2017 Apr 01; 101(7):2747-2766. PubMed ID: 28013405
    [Abstract] [Full Text] [Related]

  • 5. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.
    Zalutsky MR, Boskovitz A, Kuan CT, Pegram CN, Ayriss J, Wikstrand CJ, Buckley AF, Lipp ES, Herndon JE, McLendon RE, Bigner DD.
    Nucl Med Biol; 2012 Jan 01; 39(1):23-34. PubMed ID: 21958852
    [Abstract] [Full Text] [Related]

  • 6. EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery.
    Bao X, Pastan I, Bigner DD, Chandramohan V.
    Receptors Clin Investig; 2016 Jan 01; 3(4):. PubMed ID: 28286803
    [Abstract] [Full Text] [Related]

  • 7. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Hardcastle J, Mills L, Malo CS, Jin F, Kurokawa C, Geekiyanage H, Schroeder M, Sarkaria J, Johnson AJ, Galanis E.
    Neuro Oncol; 2017 Apr 01; 19(4):493-502. PubMed ID: 27663389
    [Abstract] [Full Text] [Related]

  • 8. Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer.
    Rech AJ, Dada H, Kotzin JJ, Henao-Mejia J, Minn AJ, Twyman-Saint Victor C, Vonderheide RH.
    Cancer Res; 2018 Aug 01; 78(15):4282-4291. PubMed ID: 29844122
    [Abstract] [Full Text] [Related]

  • 9. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.
    Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT, Schmittling RJ, Nair SK, Reap EA, Norberg PK, Herndon JE, Kuan CT, Morgan RA, Rosenberg SA, Johnson LA.
    Clin Cancer Res; 2014 Feb 15; 20(4):972-84. PubMed ID: 24352643
    [Abstract] [Full Text] [Related]

  • 10. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
    Jiang H, Gao H, Kong J, Song B, Wang P, Shi B, Wang H, Li Z.
    Cancer Immunol Res; 2018 Nov 15; 6(11):1314-1326. PubMed ID: 30201736
    [Abstract] [Full Text] [Related]

  • 11. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
    Chen M, Sun R, Shi B, Wang Y, Di S, Luo H, Sun Y, Li Z, Zhou M, Jiang H.
    Biomed Pharmacother; 2019 May 15; 113():108734. PubMed ID: 30849636
    [Abstract] [Full Text] [Related]

  • 12. OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.
    Shibahara I, Saito R, Zhang R, Chonan M, Shoji T, Kanamori M, Sonoda Y, Kumabe T, Kanehira M, Kikuchi T, So T, Watanabe T, Takahashi H, Iwabuchi E, Tanaka Y, Shibahara Y, Sasano H, Ishii N, Tominaga T.
    Mol Cancer; 2015 Feb 15; 14():41. PubMed ID: 25744203
    [Abstract] [Full Text] [Related]

  • 13. Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.
    Rao G, Latha K, Ott M, Sabbagh A, Marisetty A, Ling X, Zamler D, Doucette TA, Yang Y, Kong LY, Wei J, Fuller GN, Benavides F, Sonabend AM, Long J, Li S, Curran M, Heimberger AB.
    Clin Cancer Res; 2020 Sep 01; 26(17):4699-4712. PubMed ID: 32554515
    [Abstract] [Full Text] [Related]

  • 14. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.
    Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, Feldman SA, Chinnasamy N, Kuan CT, Song H, Zhang W, Fine HA, Rosenberg SA.
    Hum Gene Ther; 2012 Oct 01; 23(10):1043-53. PubMed ID: 22780919
    [Abstract] [Full Text] [Related]

  • 15. The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells.
    Estrada-Bernal A, Lawler SE, Nowicki MO, Ray Chaudhury A, Van Brocklyn JR.
    J Neurooncol; 2011 May 01; 102(3):353-66. PubMed ID: 20938717
    [Abstract] [Full Text] [Related]

  • 16. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
    Sugii N, Matsuda M, Okumura G, Shibuya A, Ishikawa E, Kaneda Y, Matsumura A.
    Cancer Sci; 2021 Jan 01; 112(1):81-90. PubMed ID: 33155337
    [Abstract] [Full Text] [Related]

  • 17. AB020. Flagellin synergistically enhances anti-tumor effect of EGFRvIII peptide in a glioblastoma-bearing mouse brain tumor model.
    Jung S, Lim SH, Choi JM, Liu ZP.
    Chin Clin Oncol; 2024 Aug 01; 13(Suppl 1):AB020. PubMed ID: 39295338
    [Abstract] [Full Text] [Related]

  • 18. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
    Nitta Y, Shimizu S, Shishido-Hara Y, Suzuki K, Shiokawa Y, Nagane M.
    Cancer Med; 2016 Mar 01; 5(3):486-99. PubMed ID: 26778701
    [Abstract] [Full Text] [Related]

  • 19. CD40 agonist engineered immunosomes modulated tumor microenvironment and showed pro-immunogenic response, reduced toxicity, and tumor free survival in mice bearing glioblastoma.
    Gaur V, Tyagi W, Das S, Ganguly S, Bhattacharyya J.
    Biomaterials; 2024 Dec 01; 311():122688. PubMed ID: 38943821
    [Abstract] [Full Text] [Related]

  • 20. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
    Shen CJ, Yang YX, Han EQ, Cao N, Wang YF, Wang Y, Zhao YY, Zhao LM, Cui J, Gupta P, Wong AJ, Han SY.
    J Hematol Oncol; 2013 May 09; 6():33. PubMed ID: 23656794
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.